home / stock / mnpr / mnpr news

MNPR News and Press, Monopar Therapeutics Inc. From 11/01/23

Stock Information
Company Name: Monopar Therapeutics Inc.
Stock Symbol: MNPR
Market: NASDAQ
Website: monopartx.com
Menu
MNPR MNPR Quote MNPR Short MNPR News MNPR Articles MNPR Message Board
Get MNPR Alerts

News, Short Squeeze, Breakout and More Instantly...
MNPR - Monopar to Present Data at today's Connective Tissue Oncology Society (CTOS) Annual Meeting

2023-11-01 09:18:55 ET DENVER, Colo., Nov 1, 2023 ( www.247marketnews.com )- Monopar Therapeutics Inc (NASDAQ: MNPR) stated, this morning, that it’s presenting data, from its ongoing Phase 1b open-label, dose-escalating clinical trial of camsirubicin in patients with advanced sof...
MNPR - Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will present data from its ongoing...

MNPR - Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Andrew J. Cittadine, Monopar’s Chief Operating Officer, will present ...

MNPR - Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will pr...
MNPR - Monopar Therapeutics GAAP EPS of -$0.16 beats by $0.03

2023-08-10 12:07:10 ET Monopar Therapeutics press release ( NASDAQ: MNPR ): Q2 GAAP EPS of -$0.16 beats by $0.03 . Cash, cash equivalents and short­-term investments as of June 30, 2023 were $10.2 million. The Company estimates its cash, cash equivalents and ...

MNPR - Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Camsirubicin Phase 1b Trial Currently at 5th Dose­-Level (650 mg/m 2 ), Generating Encouraging Results MNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies WILMETTE, Ill., Au...

MNPR - Monopar Provides Encouraging Camsirubicin Clinical Data Update

WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today provided an update from its currently enrolling multi-center open-label Phase 1b clin...
MNPR - Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced a collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the Nati...

MNPR - Monopar to Participate in the Radiopharma Forum by the Lake 2023

WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will partic...

MNPR - Monopar to Participate in the Maxim Group's Healthcare Virtual Conference

WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will partic...
Previous 10 Next 10